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Background: Ion channels play a critical role in a wide variety of biological processes, including the development of
human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.
Methods: We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that
are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of
ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A
molecular signature consisting of ion channel genes (IC30) is identified by Spearman’s rank correlation test conducted
between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic
power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank
test.
Results: 22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation
status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion
channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the
discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation
cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological
prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone
receptor status, and p53 mutation status.
Conclusions: We identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic
biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor
pathology could provide new targets for therapy in human cancers.
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Ion channels are membrane proteins expressed in vari-
ous tissues that allow the passage of ions across bio-
logical membranes. Ion transport is a key component in
a wide variety of biological processes including electrical
impulse generation and conduction along nerves, fluid
balancing within cells and across cell membranes, and
signal transduction within and among cells. In addition,
ion channels are known to play critical roles in gene
expression, hormone secretion, muscle contraction,* Correspondence: haena@cau.ac.kr; tongzhou@uic.edu
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reproduction in any medium, provided the orimmune response, cell volume regulation, and cell prolif-
eration [1-7]. Because of the involvement of ion channels
in diverse biological functions, defects in the expression
and functional activity of ion channels can cause disease
in many tissues [8]. The number of human diseases re-
lated with ion channel malfunction has grown rapidly
over the past few years [4,9,10]. In particular, there is in-
creasing evidence that ion channels, including both
voltage-gated and ligand-gated channels, are involved in
the progression and pathology of diversified human can-
cers [6,7,11-17]. For example, voltage-gated potassium
(K+) (Kv) channels and calcium (Ca2+)-activated K+
(KCa) channels are known to control tumor cell prolifer-
ation through the modulation of membrane potential in
breast, colon, and prostate cancers [12,14,15]. TransientThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ko et al. Molecular Cancer 2013, 12:106 Page 2 of 17
http://www.molecular-cancer.com/content/12/1/106receptor potential (TRP) channels are involved in vascular
permeability and angiogenesis and have been implicated in
tumor growth and metastasis [18,19]. Several ligand-gated
channels, such as nicotinic acetylcholine receptors, affect
neoplastic progression by regulating tumor cell prolifera-
tion, apoptosis, and angiogenesis [20-23]. More impor-
tantly, the expression level of ion channels is potentially
able to serve as a prognostic index in human cancers
for clinical purposes. For instance, TRPM1, a TRP cat-
ion channel, is an indicator of melanoma aggressiveness
[24] and expression of the Ca2+-selective cation channel
TRPV6 is a prognostic marker for tumor progression in hu-
man prostate cancer [25]. In addition, the long TRP channel
TRPM8 might serve as a prognostic marker for androgen-
unresponsive and metastatic prostate cancer [26] and
the expression of SCN9A, a voltage-gated sodium (Na+)
channel, is also useful for prognostic purposes in pros-
tate cancer [27].
Breast cancer is the most common invasive cancer in
women worldwide. It is also the principal cause of death
from cancer among women globally [28]. A large num-
ber of breast cancer studies sought to understand the
molecular mechanisms of cancer origin, progression,
and invasion that lead to metastasis, and many of these
studies have underlined the involvement of ion channels
in breast cancer. For example, KCa channels contribute
to breast tumor migration and progression [29,30] and
TRP channels are strongly correlated with breast tumor
cell proliferation [31]. In addition, the upregulation of
several voltage-gated Na+ (NaV) channels is associated
with metastatic process in breast cancer [32]; however,
most of these studies focus on only one ion channel or
one type of ion channel. So far, there is no clear picture
on the overall expression profiling of different ion chan-
nel genes in breast cancer. High-throughput “omic”
technologies make it possible to scan all ion channel
genes rather than focusing on a single gene or gene fam-
ily [33]. In this study, we looked to identify molecular
signatures consisting of multiple genes from different
ion channel families that are implicated in the pathology
of human breast cancer. Firstly, we investigated the asso-
ciation of ion channel genes with p53 mutation status in
breast tumors. The tumor suppressor p53 is known to
play a critical role in regulating the cell cycle and is thus
involved in preventing cancer. Mutations in p53 are
strongly associated with poor clinical outcome in breast
cancer patients [15,23]. Comparison between the p53
mutant and wild-type groups showed that ion channel
genes are associated with more aggressive and thera-
peutically refractory tumors [15]. Secondly, we identified
the ion channel genes that were differentially expressed
between estrogen receptor (ER) positive and negative
breast cancer patients. About 75% of all breast cancers
are ER positive, which grow in response to the hormoneestrogen. ER is a powerful prognostic marker and an ef-
ficient target for the treatment of hormone-dependent
breast cancer [26]. Identification of the ER-related ion
channels helps us understand the role of ER in the de-
velopment and progression of breast cancer. Thirdly, we
investigated the relationship between ion channel gene
expression and histological tumor grade in breast cancer.
We identified a molecular signature consisting of 30 ion
channel genes (IC30), which significantly correlated with
tumor grade. We demonstrate that IC30 is a robust
prognostic biomarker to predict clinical outcome in
breast cancer, and is independent of standard clinical
and pathological prognostic factors including patient
age, lymph node status, tumor size, tumor grade, ER sta-
tus, and progesterone receptor (PR) status. The perform-
ance of IC30 was also validated in several independent
cohorts from different parts of the world (Table 1).
Results
Differentially expressed ion channel genes between p53
mutant and wild-type tumors
280 ion channel genes were collected for this study
(Additional file 1: Table S1). We aim to identify candi-
date ion channels that are implicated in breast cancer
based on gene expression profiling. We first explored
the difference in ion channel gene expression between
p53 mutant and wild-type breast tumors in the discovery
SIN cohort. There were 58 samples with p53 mutations
resulting in protein-level changes and 193 samples with
a wild-type genotype [15]. In total, 22 ion channel genes
were identified as differentially expressed between
the two groups. Five ion channel genes were upregulated
in p53 mutant tumors, including KCNE3, KCNN4,
and MCOLN2; while 17 ion channel genes were
downregulated, including ANO1, KCNMA1, and TPCN1
(Table 2 and Figure 1). Among these differentially
expressed genes, all the Ca2+ channel (CACNA1D,
CACNA2D1, and CACNA2D2) and Na+ (SCN7A and
SCNN1A) channel genes were downregulated in mutant
tumors. In contrast, the expression pattern of K+ chan-
nel and chloride (Cl-) channels was more heterogeneous.
Genome-scale inspection indicated a significant enrich-
ment of ion channel genes among the genes regulated
by p53 mutation status (P = 0.027 by Fisher’s exact test).
To test the reliability of the above results in another
cohort, we accessed a publicly available microarray
dataset on breast cancer (FRA) where p53 mutation sta-
tus was known. Unsupervised hierarchical cluster ana-
lysis demonstrated a very similar expression pattern of
the 22 differentially expressed ion channel genes be-
tween the SIN and FRA cohorts (Figure 2). We evalu-
ated the statistical significance in hierarchical cluster
analysis by approximately unbiased P-value (AU) (see
Methods for details). In the SIN cohort, the hierarchical
Table 1 Gene expression datasets of breast cancer
Organization of data source Abbreviation GEO accession Reference
Genome Institute of Singapore, Singapore SIN GSE3494 [15]
Institut Paoli-Calmettes Marseille, France FRA GSE21653 [16]
Siemens Medical Solutions Diagnostics GmbH, Germany GER GSE11121 [34]
Netherlands Cancer Institute, Netherlands NED -a [21]
Karolinska Institutet, Sweden SWE GSE1456 [18]
Koo Foundation SYS Cancer Center, Taiwan TWN GSE20685 [19]
Nuvera Biosciences Inc, United States USA1 GSE25066 [20]
Veridex LLC, United States USA2 GSE2034 [27]
aExpression data for NED are publicly available from http://bioinformatics.nki.nl/data.php.
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highly robust (AU = 0.993 for the upregulated cluster
and AU = 0.963 for the downregulated cluster). Similar
results were obtained for the FRA cohort (AU = 0.985
for the upregulated cluster and AU = 0.990 for the
downregulated cluster). Two-tailed t-tests also indicated
that 15 out of the 22 genes were significantly (adjusted
P < 0.05) dysregulated between p53 mutant and wild-




ANO1 anoctamin 1, calcium activated chloride channel
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D su
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subun
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subun
CLCA2 chloride channel accessory 2
CLIC5 chloride intracellular channel 5
CLIC6 chloride intracellular channel 6
GLRB glycine receptor, beta
KCND3 potassium voltage-gated channel, Shal-related subfamily,
KCNE3 potassium voltage-gated channel, Isk-related family, mem
KCNE4 potassium voltage-gated channel, Isk-related family, mem
KCNJ3 potassium inwardly-rectifying channel, subfamily J, memb
KCNK1 potassium channel, subfamily K, member 1
KCNK6 potassium channel, subfamily K, member 6
KCNMA1 potassium large conductance calcium-activated channel,
KCNN4 potassium intermediate/small conductance calcium-activa
MCOLN2 mucolipin 2
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4
SCN7A sodium channel, voltage-gated, type VII, alpha subunit
SCNN1A sodium channel, non-voltage-gated 1 alpha subunit
TPCN1 two pore segment channel 1
TRPC1 transient receptor potential cation channel, subfamily C, m
aFold change is calculated by dividing the mean expression of p53 mutant tumor b
bP-value is calculated by two-tailed t-test and adjusted by Benjamini & Hochberg coS2). The direction of differential expression in the SIN
cohort was reproduced in the FRA cohort (Figure 3A).
Differentially expressed ion channel genes between ER
positive and negative patients
We compared ion channel gene expression between ER
positive and negative patients in the SIN cohort. A total
of 213 patients were identified as ER positive while 34






bunit 0.32 < 0.001
it 1 0.79 0.002





member 3 0.46 < 0.001
ber 3 1.34 < 0.001
ber 4 0.25 < 0.001
er 3 0.51 < 0.001
1.44 < 0.001
0.80 0.010
subfamily M, alpha member 1 0.65 < 0.001
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Figure 1 Boxplot of expression of the genes differentially expressed between p53 mutant and wild-type tumors. Twenty-two ion
channel genes were found to be differentially expressed between the two groups. Light-grey represents wild-type group while dark-grey
represents mutant group. Y-axis: log2-transformed expression values.
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between the two groups; 16 genes were upregulated in
ER positive patients while 8 genes were downregulated
(Table 3 and Figure 4). Among these differen-
tially expressed genes, all the Ca2+ channels (except
CACNA1A) and Na+ channel genes were upregulated in
the ER positive group, whereas the expression pattern of
K+ channel and Cl- channels was more heterogeneous.
Nineteen out of the 24 differentially expressed genes
overlapped with the genes differentially expressed be-
tween p53 mutant and wild-type tumors (Figures 1 and
4), which is statistically significant (P < 0.001 by cumula-
tive hypergeometric distribution function). Among these
common genes, all the downregulated genes in ER
positive patients were upregulated in the p53 mutant
group and vice versa, which is consistent with previous
findings that patients with negative ER status share com-
mon pathology with patients harboring mutant p53
[25,35]. We also found a significant enrichment of ion
channel genes among the genes dysregulated by ER sta-
tus (P = 0.013 by Fisher’s exact test).We next checked the expression profiling the 24 ER
status related ion channel genes in three independent
cohorts (FRA, USA1, and USA2) where ER status was
known. The heatmaps generated by unsupervised hier-
archical cluster analysis demonstrated an analogous ex-
pression profiling for the 24 ion channel genes among
the discovery and validation cohorts (Additional file 2:
Figures S1, S2, S3 and S4). A side-by-side comparison
between Table 3 and Additional file 1: Table S3 revealed
that the 24 genes were significantly (adjusted P < 0.05)
dysregulated by ER status in at least one out of the three
validation cohorts. The direction of differential expres-
sion in the SIN cohort was consistent with that in the
FRA, USA1, and USA2 cohorts (Figure 3B).
Correlation between tumor grade and expression of ion
channel genes
To determine the relationship between tumor progres-
sion and ion channel gene expression, we linked gene
expression level with histological tumor grade in the SIN
cohort, using the Spearman’s rank correlation test. The
SIN
FRA














































Figure 2 Heatmaps of expression of the genes differentially expressed between p53 mutant and wild-type tumors. The differentially
expressed ion channel genes were derived from the discovery cohort (SIN) and verified in the FRA cohort. Each row in the heatmaps was
labelled with the corresponding gene symbol. The columns labelled with “-” denote p53 mutant tumors. Red represents relatively increased gene
expression while blue represents down-regulation. The horizontal dotted line separates the down- and up- regulated gene clusters.
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nificantly (adjusted P < 0.05) correlated with tumor grade
(Table 4). Eleven out of the 30 genes showed a positive
correlation between expression and tumor grade while
the other 19 genes showed a negative pattern (Figure 5).
Given the fact that tumor grade reflects the differenti-
ation of breast cancer cells, we identified 11 upregulated
and 19 downregulated ion channel genes in more
aggressive breast tumors. Among these 30 genes, 19
genes were also differentially expressed between the p53
mutant and wild-type tumors. The number of the over-
lapping dysregulated genes was statistically significant
(P < 0.001 by cumulative hypergeometric distribution
function). Positive correlation between expression and
tumor grade corresponds to upregulation in p53 mutant
tumors and vice versa, which confirms the well-
established findings that p53 mutations link to higher-
grade breast cancer and potentially poorer clinical
outcomes [32,33,36,37]. Similar to the results describedabove for p53/ER status, ion channel genes were also
significantly enriched among all the genes that were re-
gulated by tumor grade (P = 0.003 by Fisher’s exact test).
Because of the availability of tumor grade information
in the FRA, GER, and USA1 cohorts, we tested the ex-
pression pattern of the above 30 genes in these 3 inde-
pendent datasets. We observed a significant correlation
between the expression and tumor grade in at least
one validation cohort for each gene, except for TPCN2
(Additional file 1: Table S4). The correlation coefficients
for each gene were largely concordant across the discovery
and validation cohorts (Figure 3C).
Prognostic molecular signature composed of ion
channel genes
We hypothesized that the 30 ion channel genes associ-
ated with tumor histological grade would be predictive
of tumor outcome in breast cancer patients. We






















































































































































































































































































































































































Figure 3 Validation of ion channel gene expression profiling in breast cancer. (A) Heatmap of log2-transformed fold change of gene
expression level between p53 mutant and wild-type tumors (mutant/wild-type). In the SIN cohort, 5 genes were up-regulated (log2-transformed
fold change > 0) while 17 genes were down-regulated (log2-transformed fold change < 0) in mutant tumors. The vertical dotted line separates
the down- and up- regulated gene clusters (AU = 1 for both clusters). (B) Heatmap of log2-transformed fold change of gene expression level
between ER positive and negative groups (ER positive/negative). In the SIN cohort, 16 genes were up-regulated (log2-transformed fold change >
0) while 8 genes were down-regulated (log2-transformed fold change < 0) in ER positive patients. The white cells in the heatmap mean the gene
expression data are unavailable in the corresponding datasets. The vertical dotted line separates the down- and up- regulated gene clusters (AU =
0.995 for both clusters). (C) Heatmap of Spearman’s rank correlation coefficient. We found 30 ion channel genes with significant Spearman’s rank
correlation between gene expression and histological grade in SIN cohort. Correlation coefficient > 0 means that gene is upregulated in the patients
with higher grade while negative correlation coefficient indicates down-regulation in the patients with higher grade. The white cells in the heatmap
mean the gene expression data are unavailable in the corresponding datasets. The vertical dotted line separates the down- and up- regulated gene
clusters (AU = 1 for both clusters).
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bined gene expression information in the IC30 with the
Spearman’s rank correlation coefficients (ρ) listed in
Table 4. IC30 positive patients were defined as those
having a risk score greater than the group median score
and the other patients were assigned as IC30 negative.We tested the ability of the risk score to stratify patients
into prognostic groups in the SIN cohort and the seven
validation cohorts (FRA, GER, NED, SWE, TWN, USA1,
and USA2). Kaplan-Meier survival analyses were used to
compare the IC30 positive and negative groups and de-
termined statistical significance by log-rank tests. The







ANO1 anoctamin 1, calcium activated chloride channel 2.09 < 0.001
CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 0.65 0.043
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit 5.59 < 0.001
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 1.30 0.033
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 2.61 < 0.001
CLCA2 chloride channel accessory 2 0.46 0.017
CLIC4 chloride intracellular channel 4 0.75 0.008
CLIC6 chloride intracellular channel 6 5.86 < 0.001
GABRP gamma-aminobutyric acid (GABA) A receptor, pi 0.20 0.020
GLRB glycine receptor, beta 3.42 < 0.001
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 0.72 0.013
KCND3 potassium voltage-gated channel, Shal-related subfamily, member 3 2.36 < 0.001
KCNE3 potassium voltage-gated channel, Isk-related family, member 3 0.75 0.003
KCNE4 potassium voltage-gated channel, Isk-related family, member 4 12.64 < 0.001
KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3 6.22 < 0.001
KCNK6 potassium channel, subfamily K, member 6 1.82 < 0.001
KCNMA1 potassium large conductance calcium-activated channel, subfamily M, alpha member 1 1.45 0.035
KCNN4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 0.42 < 0.001
KCNS3 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 1.58 0.028
MCOLN2 mucolipin 2 0.46 0.002
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 1.82 < 0.001
SCN7A sodium channel, voltage-gated, type VII, alpha subunit 1.71 0.009
SCNN1A sodium channel, non-voltage-gated 1 alpha subunit 2.00 < 0.001
TPCN1 two pore segment channel 1 1.38 < 0.001
aFold change is calculated by dividing the mean expression of ER positive tumor by the mean expression of ER negative tumor.
bP-value is calculated by two-tailed t-test and adjusted by Benjamini & Hochberg correction.
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breast cancer survival in all the cohorts (P < 0.01) except
for the GER cohort (a marginal P = 0.066) (Figure 6).
This association between IC30 status and survival was
also confirmed by univariate Cox proportional hazard
regression of survival. IC30 positive patients had a 1.98-
fold increased risk for death in the SIN cohort, 1.99-fold
in the FRA cohort, 1.73-fold in the GER cohort, 1.81-
fold in the NED cohort, 4.33-fold in the SWE cohort,
1.82-fold in the TWN cohort, 3.11-fold in the USA1 co-
hort, and 1.71-fold in USA2 cohort (Table 5).
Independence of IC30 from other clinicopathological
factors
We investigated the performance of the IC30 signature
in comparison with clinicopathological variables associ-
ated with prognosis in breast cancer in the USA1 cohort,
the largest dataset in this study. A multivariate Cox re-
gression of survival indicated that IC30 status remained
a significant covariate in relation to the standardclinicopathological factors in breast cancer, including
patient age, lymph node status, tumor size, tumor grade,
and ER and PR status (Table 6). Patients were stratified
according to respective clinicopathological factors. For
patients aged < 50 and ≥ 50, the IC30 positive patients
had a significant 2.37-fold (P = 0.003) and 4.21-fold (P <
0.001) increased risk for death, respectively. For patients
with and without lymph node involvement, the IC30
positive patients had a 2.05-fold (P = 0.157) and 2.72-fold
(P < 0.001) increased risk for death, respectively. For pa-
tients with tumor size < T3 and ≥ T3, the IC30 positive
patients had a significantly increased risk for death of
3.61-fold (P < 0.001) and 2.78-fold (P < 0.001), respect-
ively. For patients with lower (1 or 2) and higher (3)
tumor grade, the IC30 positive patients had a signifi-
cantly 6.91-fold (P < 0.001) and 1.67-fold (P = 0.044) in-
creased risk for death, respectively. For patients with ER
negative and positive status, the IC30 positive patients
had an increased risk for death of 1.30-fold (P = 0.275)

































































































































































































































































































































Figure 4 Boxplot of expression of the genes differentially expressed between ER positive and negative patients. Twenty-four ion
channel genes were found to be differentially expressed between the two groups. Light-grey represents ER negative group while dark-grey
represents ER positive group. Y-axis: log2-transformed expression values.
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http://www.molecular-cancer.com/content/12/1/106positive patients with PR negative and positive status
had a significantly 1.65-fold (P = 0.030) and 2.35-fold
(P = 0.021) increased risk for death, respectively. Kaplan-
Meier survival analysis also demonstrated a significantly
reduced survival for IC30 positive patients in each sub-
set grouped by age, lymph node status, and tumor size
(Figure 7). In addition, univariate Cox regressions of sur-
vival confirmed that the IC30 signature was a superior
survival predictor in the USA1 cohort, in comparison
with age, tumor size, and tumor grade (Additional file 1:
Table S5).
We also checked the independent predictive power of
the IC30 signature in the FRA cohort, where informa-
tion on age, tumor grade, ER status, PR status, and p53
mutation status is available. A multivariate Cox regres-
sion of survival indicated that the IC30 signature
was the only significant survival predictor (P = 0.014)
(Table 7). Univariate Cox regressions of survival also
confirmed that the IC30 signature was the most signifi-
cant prognostic factor in the FRA cohort, in comparisonwith age, tumor grade, ER and PR status, and p53 muta-
tion status (Additional file 1: Table S6). Taken together,
these results suggest that IC30 is associated with clinical
outcome and is an independent prognostic factor.
Discussion
Ion channels are implicated in many physiological pro-
cesses and also play a pivotal role in the development of
cancers; however, it is currently difficult to assign a spe-
cific mechanism for each ion channel in the prolifera-
tion, invasion, and metastasis of tumor cells [17,24].
Here, we investigated the pathological role of ion chan-
nel genes in breast cancer with respect to gene expres-
sion level. We tested the association of ion channel
genes with p53 mutation status, ER status, and tumor
histological grade: 22 ion channel genes were found to
be dysregulated between p53 mutant and wild-type tu-
mors, 24 ion channel genes were differentially expressed
between ER positive and negative patients, and the ex-
pression level of 30 ion channel genes was significantly
Table 4 Correlation between gene expression and histological tumor grade
Gene
symbol
Gene title ρa Adjusted
P-valueb
ANO1 anoctamin 1, calcium activated chloride channel −0.23 < 0.001
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit −0.42 < 0.001
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 −0.28 < 0.001
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 −0.30 < 0.001
CLIC1 chloride intracellular channel 1 0.26 < 0.001
CLIC4 chloride intracellular channel 4 0.16 0.022
CLIC5 chloride intracellular channel 5 −0.22 0.001
CLIC6 chloride intracellular channel 6 −0.33 < 0.001
GLRB glycine receptor, beta −0.35 < 0.001
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 0.15 0.023
KCND3 potassium voltage-gated channel, Shal-related subfamily, member 3 −0.39 < 0.001
KCNE3 potassium voltage-gated channel, Isk-related family, member 3 0.23 < 0.001
KCNE4 potassium voltage-gated channel, Isk-related family, member 4 −0.38 < 0.001
KCNK1 potassium channel, subfamily K, member 1 0.25 < 0.001
KCNMA1 potassium large conductance calcium-activated channel, subfamily M, alpha member 1 −0.30 < 0.001
KCNN4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 0.23 < 0.001
MCOLN2 mucolipin 2 0.25 < 0.001
P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 −0.24 < 0.001
PKD1 polycystic kidney disease 1 (autosomal dominant) −0.17 0.012
PKD2 polycystic kidney disease 2 (autosomal dominant) −0.19 0.004
SCN1B sodium channel, voltage-gated, type I, beta subunit −0.27 < 0.001
SCN7A sodium channel, voltage-gated, type VII, alpha subunit −0.41 < 0.001
SCNN1A sodium channel, non-voltage-gated 1 alpha subunit −0.18 0.008
TPCN1 two pore segment channel 1 −0.26 < 0.001
TPCN2 two pore segment channel 2 0.17 0.013
TRPC1 transient receptor potential cation channel, subfamily C, member 1 −0.25 < 0.001
TRPM4 transient receptor potential cation channel, subfamily M, member 4 −0.21 0.002
VDAC1 voltage-dependent anion channel 1 0.21 0.002
VDAC2 voltage-dependent anion channel 2 0.22 0.001
VDAC3 voltage-dependent anion channel 3 0.26 < 0.001
aρ is the Spearman’s rank correlation coefficient.
bP-value is calculated by Spearman’s rank correlation test and adjusted by Benjamini & Hochberg correction.
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http://www.molecular-cancer.com/content/12/1/106correlated with histological grade. There is a large over-
lap between the three differentially expressed gene lists,
which suggests a common ion channel-related biological
mechanism underlying the different pathological pheno-
types. The prognostic value of p53 mutation status
has been well characterized in previous studies
[15,29-31,35]. The frequency of p53 mutations is higher
in ER negative breast cancer [25,35]. Mutant p53 and/or
negative ER status are often associated with a high rate
of proliferation, a high histological grade, and a poor
prognosis [32,33,36,37]. Therefore, it is reasonable that
several common ion channel genes are associated with
p53 mutation status, ER status, and tumor histologicalgrade, although the causal relationship between these
three factors is still controversial.
Gene expression-based molecular signatures have been
proven as prognostically valuable in several human can-
cers [38-42]. Gene signatures that work cooperatively
with known clinicopathological factors may enhance
prediction accuracy when identifying patients at higher
risk for relapse and death. Our proposed molecular sig-
nature that is composed of 30 ion channel genes (IC30)
associated with tumor grade is a promising prognostic
marker. IC30 was solely developed based on the discov-
ery cohort and its prognostic power of IC30 was













































































































































































































































































Figure 5 Boxplot of expression of the 30 ion channel genes associated with histological grade. The red points and lines indicate the
geometric mean of expression in each category. X-axis: histological grade of breast cancer; Y-axis: log2-transformed expression values.


























































































































































































































Figure 6 Kaplan-Meier curves for the patients from eight independent breast cancer cohorts. Panels from A to H denote the SIN, FRA,
GER, NED, SWE, TWN, USA1, and USA2 cohorts, respectively. The expression of IC30 gene signature predicts poor survival in breast cancer. Red
curves are for the IC30 positive patients while blue curves are for the IC30 negative patients. IC30 positive patients were defined as those having
a IC30 risk score greater than the group median score. P-values were calculated by log-rank tests for the differences in survival between the IC30
positive and negative groups.
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http://www.molecular-cancer.com/content/12/1/106demonstrated that there were no significant multivariate
interactions between IC30 status and other clinicopatho-
logical covariates. When grouped by age, tumor size,
tumor grade, or PR status, the expression of IC30 fur-
ther stratified breast cancer patients with significant dif-
ferences in survival. A significantly increased risk of
death was also observed in IC30 positive patients with
positive lymph node status or positive ER status. How-
ever, a significant difference between IC30 positive and
negative groups among the patients with negative
ER status was not detected, which may be due to theTable 5 Univariate Cox proportional hazards regression
of survival by IC30 status for patients from 8 cohorts
Cohort Hazard ratio 95% Confidence interval P-value
SIN 1.98 (1.15, 3.44) 0.015
FRA 1.99 (1.28, 3.10) 0.002
GER 1.73 (0.96, 3.14) 0.069
NED 1.81 (1.15, 2.86) 0.010
SWE 4.33 (1.76, 10.64) 0.001
TWN 1.82 (1.17, 2.85) 0.008
USA1 3.11 (2.05, 4.70) < 0.001
USA2 1.71 (1.16, 2.51) 0.006relatively smaller sample size in this category within the
USA1 cohort. In addition, we only detected a marginal
significant association for patients with negative lymph
node status in the USA1 cohort, and a similar result was
reproduced in the GER cohort. In fact, all patients from
the GER cohort had negative lymph node status [34]
and a marginally significant difference in the risk of
death was observed between IC30 positive and negative
patients in this cohort. Taken together with previous
data, these results confirm that IC30 is not dependent
on specific values of the respective covariates status,
which enhances the identification of cancer patients at
greater risk for death.
Although IC30 gene signature was identified using the
tumor grade information, both multivariate and univari-
ate Cox regressions of survival reveal that IC30 is super-
ior to tumor grade, which suggests that the prognostic
information contained in IC30 is not limited to tumor
grade. Tumor grade only explains a small proportion of
variation (less than 25%) in expression of each IC30
gene. The significant association between tumor grade
and IC30 gene expression specifically implies that IC30
genes are actively involved in tumor pathology in
breast cancer. The combination of 30 genes contains
more quantity of information than tumor grade itself.
Table 6 Multivariate Cox proportional hazard regression of survival for the patients from the USA1 cohort
Covariate Hazard ratio 95% Confidence interval P-value
IC30 + vs. - 2.21 (1.32, 3.70) 0.002
Age (per year) 1.00 (0.98, 1.02) 0.940
Lymph node + vs. - 2.07 (1.35, 3.16) < 0.001
Tumor size ≥ T3 vs. < T3 1.73 (1.16, 2.57) 0.007
Grade 3 vs. 1,2 0.67 (0.41, 1.11) 0.119
ER + vs. - 0.58 (0.33, 1.01) 0.055































































































































































































































































































































Figure 7 Kaplan-Meier curves for the patients grouped by clinicopathological factors. IC30 is independent from other clinicopathological
factors in breast cancer. (A) Patients were stratified by age; (B) Patients were stratified by lymph node status; (C) Patients were stratified by tumor
size; (D) Patients were stratified by tumor grade; (E) Patients were stratified by ER status; and (F) Patients were stratified by PR status. Red curves
are for the IC30 positive patients while blue curves are for the IC30 negative patients. IC30 positive patients were defined as those having a IC30
risk score greater than the group median score. P-values were calculated by log-rank tests for the differences in survival between the IC30
positive and negative groups.
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Table 7 Multivariate Cox proportional hazard regression of survival for the patients from the FRA cohort
Covariate Hazard ratio 95% Confidence interval P-value
IC30 + vs. - 2.55 (1.21, 5.39) 0.014
Age (per year) 1.00 (0.98, 1.02) 0.687
Grade 3 vs. 1,2 0.79 (0.43, 1.45) 0.444
ER + vs. - 0.91 (0.33, 2.52) 0.855
PR + vs. - 1.24 (0.48, 3.18) 0.655
p53 mutant vs. wild-type 1.22 (0.70, 2.12) 0.487
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to tumor grade.
The involvement of ion channels in human cancer has
been intensively studied in the past years. However,
there is no broad consensus on the role and interplay
between ion channels and cancer. Generally, ion chan-
nels are thought to “assist” cancer by tumor-related
cellular behaviors such as proliferation, apoptosis, migra-
tion, or angiogenesis [14,17,43,44]. However, it is diffi-
cult to assign a detailed role for each ion channel in
cancer pathology. In breast cancer, accumulating evi-
dence indicates that K+ channels play important roles in
regulating tumor cell proliferation, cell cycle progression,
and apoptosis [12,45,46]. Although a significant over-
expression of K+ channels has been correlated with
human breast cancer cells [45,47-51], here we report a
heterogeneous expression profiling in K+ channel genes.
Dysregulation in both directions was observed in K+
channel genes within the IC30. Four K+ channel genes
in the IC30 were upregulated in high-grade tumors. For
example, KCNN4, encoding an intermediate conduct-
ance KCa channel (KCa3.1), is among the upregulated K
+
channel genes in the IC30 in high-grade tumors. The ex-
pression pattern of KCa3.1 was confirmed by a recently
published study where KCa3.1 mRNA and protein were
more highly expressed in grade 3 tumors than in both
grades 1 and 2 [52]. On the contrary, three K+ channel
genes within the IC30 were downregulated in tumors
with higher grade, which includes KCNMA1 encoding
the BK channel alpha subunit. The negative correlation
for KCNMA1 between expression and tumor grade was
in accord with four independent cohorts. However, in-
creased expression of KCNMA1 was found in metastatic
breast cancer in the brain compared to metastatic breast
cancers in other organs [53], which suggests a more
complicated pathological role for the BK channel in
tumor metastasis.
Gene expression of Cl- channels also demonstrated a
heterogeneous pattern in breast cancer. We reported
two up- and two downregulated Cl- intracellular channel
genes in high-grade tumors in the IC30. Among them,
CLIC4 was found to be involved in skin cancer [54];
however, the exact role of CLIC4 is unclear. Besides Cl-
intracellular channels, the Ca+ activated Cl- channelCLCA2 was downregulated in breast cancer and is a
candidate tumor suppressor gene [55]. We show here
that the CLCA2 gene was upregulated in p53 mutant
and/or ER negative breast tumors. In fact, the tumori-
genicity of breast cancer was related with a loss of
CLCA2 [56,57]. CLCA2 is a p53-inducible inhibitor of
breast tumor proliferation [55]. However, the reason
why CLCA2 expression is associated with p53 mutation
status is beyond the scope of this study.
Ca2+ is an essential regulator of the cell cycle and is indis-
pensable for cell proliferation [14]. Increased expression of
voltage-gated Ca2+ channels has been observed in colon
cancer cells [58] and small cell lung cancers [59]. However,
all 3 voltage-gated Ca2+ ion channel genes in the IC30 were
downregulated in p53 mutant tumors and/or high-grade
tumors. Apart from these voltage-gated Ca2+ channels, the
TRP family is also important to provide a Ca2+ influx path-
way such that Ca2+ influx may occur through voltage-gated
Ca2+ channels [14]. Several studies have demonstrated that
the expression of TRP channels is significantly upregulated
in breast tumor tissue and breast cancer cell lines [60-63],
which is related to malignant growth and cancer progres-
sion [64]. However, a paradoxical result was observed in
our study. PKD1, PKD2, and TRPC1, which are within the
IC30 and belong to the TRP family, were downregulated in
patients with p53 mutant tumors and/or of higher histo-
logical grade. This expression pattern is consistent in sev-
eral of the validation cohorts.
Conflicting results were also seen in Na+ channel genes.
Decreased expression in high-grade tumors was found for
the three Na+ channel genes in the IC30, which was con-
firmed by the validation cohorts. However, increased ex-
pression of voltage-gated Na+ channels has been reported
in several cancer types, including breast, prostate, and lung
cancer [65-68]. Na+ channels were thought to enhance the
invasiveness of cancer cells by increasing H+ efflux [66] and
by stimulating cysteine cathepsin activity [69]. The precise
mechanism of Na+ channels in tumor development re-
mains unclear [70]. The discrepancy between our results
and previous observation may be due to the discrepancy
between mRNA expression, protein expression, and chan-
nel activity. Our study focused on mRNA abundance.
However, protein expression and activity is not directly
correlated to mRNA expression. Post-transcriptional
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mRNA to protein abundance ratios [71].
Voltage-dependent anion channels (VDACs) are a
class of ion channel located in the outer mitochondrial
membrane [72]. We observed a consistent and signifi-
cant positive correlation between gene expression and
tumor grade for the three VDAC genes in the IC30. A
recently published study indicated that higher VDAC1
expression level predicts poor outcome in non-small cell
lung cancers [73]. Here, we expanded this finding to
breast cancer and the other 2 genes in VDAC family.
Conclusions
In summary, we investigated the gene expression profile
of ion channels in breast cancer with respect to p53 mu-
tation status, ER status, and histological grade. We show
that there are numerous common ion channel genes, in-
cluding ANO1, CACNA1D, CACNA2D1, CACNA2D2,
CLIC6, GLRB, KCND3, KCNE4, KCNMA1, KCNN4,
MCOLN2, P2RX4, SCN7A, SCNN1A, and TPCN1, that
are differentially expressed with a change in p53 muta-
tion status, ER status, and histological grade. The ex-
pression pattern of some ion channels, including several
potassium, calcium, and sodium channels, is contradict-
ory to previously published results derived from breast
cancer cell lines, animal models, and/or human patients.
We also identified a molecular gene signature IC30,
which represents a promising diagnostic and prognostic
biomarker in breast cancer. Further investigation into
the role of ion channels in tumor pathology could pro-
vide new targets for therapy in multiple human cancers.
Methods
Ion channel genes
The definition of human ion channel genes was obtained
from IUPHAR-DB [74] and GeneCards [5,9]. In total, we
collected 280 ion channel genes, including 5 Ca+ activated
Cl- channels, 6 Cl- intracellular channels, 9 voltage-
sensitive Cl- channels, 1 mid-1-related Cl- channel, 12 Kca
channels, 48 Kv channels, 26 voltage-gated Ca+ channels,
14 NaV channels, 15 two-pore K+ channels, 9 CatSper and
two-pore channels, 16 inwardly rectifying K+ channels, 4
non-voltage-gated Na+ channels, 28 TRP channels, 10 cyc-
lic nucleotide-regulated channels, 20 GABAA receptors, 5
5-HT3 receptors, 5 glycine receptors, 18 ionotropic glu-
tamate receptors, 16 nicotinic acetylcholine receptors, 7
P2X receptors, 3 voltage-dependent anion channels, 1
voltage-gated proton channel, 1 voltage-independent cat-
ion channel, and 1 zinc activated ligand-gated ion channel
(Additional file 1: Table S1).
Gene expression data
Eight independent microarray breast cancer datasets
from Singapore (SIN) [15], France (FRA) [16], Germany(GER) [34], Netherlands (NED) [21], Sweden (SWE)
[18], Taiwan (TWN) [19], and the United States (USA1
and USA2) [20,27], were obtained for use in this study
(Table 1). These datasets were chosen based on the large
number of samples, the availability of clinical outcome
data, and the diversity of tumor types. We assigned the
SIN dataset as our discovery cohort and the other seven
datasets as validation cohorts.
Microarray data preprocessing
The GC robust multichip average (GCRMA) algorithm
[75] in Bioconductor was used to summarize the expres-
sion level of each probe set for the microarray data from
our discovery cohort (Affymetrix Human Genome U133
set). Only the probe sets present (determined by func-
tion “mas5calls” in the Bioconductor “affy” package) in
at least one third of the samples were retained. We fur-
ther limited our analysis to the probe sets with unique
annotations and removed genes on chromosomes X and
Y to avoid the potential confounding sex factor.
Statistical analysis
For the SIN and FRA cohorts, a two-tailed t-test was
used to identify the genes that were differentially
expressed between p53 mutant and wild-type tumors.
The genes with an adjusted P-value < 0.05 after
Benjamini & Hochberg correction [22] and fold change >
1.25 were deemed differentially expressed. The same
methods and criteria were applied to identify the genes
differentially expressed between ER positive and negative
patients in SIN, FRA, USA1, and USA2 cohorts.
The Spearman’s rank correlation test was used to de-
tect the relationship between ion channel gene expres-
sion level and tumor histological grade. We calculated
correlation coefficients and associated P-values using the
R function “cor.test” with the “spearman” method. The
genes with adjusted P-value < 0.05 after Benjamini &
Hochberg correction were assigned as differentially
expressed. We then tested the power of these tumor
grade associated genes in predicting clinical outcome in
breast cancers. Based on the relationship between gene
expression and tumor grade, we can assign a Spearman’s
rank correlation coefficient to each gene as a weight
(calculated solely from the discovery cohort). A risk
score was then calculated for each patient using a linear






Here, s is the risk score of the patient; n is the number
of differentially expressed genes; ρi denotes the
Spearman’s rank correlation coefficient of gene i; ei
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the mean and standard deviation of the gene expression
values for gene i across all samples, respectively. Patients
were then divided into high-score (IC30 positive) and
low-score (IC30 negative) groups with the median of the
risk score as the threshold value. The median of the risk
score was approximately equal to zero in each cohort
(Additional file 2: Figure S5). A high score indicated a
poor outcome. The “survival” library of the R was used
to conduct survival analysis on the risk score.
Hierarchical cluster analysis was conducted to gen-
erate the gene expression heatmaps. The statistical
significance of hierarchical cluster was evaluated by
approximately unbiased P-value (AU), which is com-
puted by multiscale bootstrap resampling. AU of a
cluster is a value between 0 and 1, which indicates
how strong the cluster is supported by data. Higher
AU means lower uncertainty of the hierarchical
cluster. The “pvclust” library of the R was used to
compute the AU values.Additional files
Additional file 1: Table S1. Ion channel genes involved in this study.
Table S2. Comparison in gene expression level between p53 mutant and
wildtype tumors in validation cohorts. Table S3. Comparison in gene
expression level between ER positive and negative tumors. Table S4.
Correlation between gene expression and histological tumor grade.
Table S5. Comparison in prognostic power between IC30 and
clinicopathological factors for the USA1 cohort. Hazard ratio was
calculated separately for each variable by univariate Cox proportional
hazard regression of survival. Table S6. Comparison in prognostic power
between IC30 and clinicopathological factors for the FRA cohort. Hazard
ratio was calculated separately for each variable by univariate Cox
proportional hazard regression of survival.
Additional file 2: Figure S1. Heatmaps of expression of the ion
channel genes differentially expressed between ER positive and negative
tumors. The differentially expressed genes were derived from the
discovery cohort (SIN). Each row in the heatmaps was labelled with the
corresponding gene symbol. The columns labelled with “-” denote ER
positive tumors. Red represents relatively increased gene expression
while blue represents down-regulation. Figure S2. Heatmaps of gene
expression in FRA cohort. The listed genes are differentially expressed
between ER positive and negative tumors in the discovery cohort (SIN).
Each row in the heatmaps was labelled with the corresponding gene
symbol. The columns labelled with “-” denote ER positive tumors. Red
represents relatively increased gene expression while blue represents
down-regulation. Figure S3. Heatmaps of gene expression in GER cohort.
The listed genes are differentially expressed between ER positive and
negative tumors in the discovery cohort (SIN). Each row in the heatmaps
was labelled with the corresponding gene symbol. The columns labelled
with “-” denote ER positive tumors. Red represents relatively increased
gene expression while blue represents down-regulation. Figure S4.
Heatmaps of gene expression in USA1 cohort. The listed genes are
differentially expressed between ER positive and negative tumors in the
discovery cohort (SIN). Each row in the heatmaps was labelled with the
corresponding gene symbol. The columns labelled with “-” denote ER
positive tumors. Red represents relatively increased gene expression
while blue represents down-regulation. Figure S5. Distribution of risk
score. The red dash lines indicate the median of risk score. There is no
significant deviation between zero and the median of risk score in each
cohort (|z| < 0.2).Abbreviations
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